These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 27032774)

  • 1. Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.
    Kollewe K; Escher CM; Wulff DU; Fathi D; Paracka L; Mohammadi B; Karst M; Dressler D
    J Neural Transm (Vienna); 2016 May; 123(5):533-40. PubMed ID: 27032774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
    J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
    Davies B; Gaul C; Martelletti P; García-Moncó JC; Brown S
    J Headache Pain; 2017 Sep; 18(1):93. PubMed ID: 28879545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience.
    Grazzi L; Usai S
    Neurol Sci; 2015 May; 36 Suppl 1():33-5. PubMed ID: 26017508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
    Negro A; Curto M; Lionetto L; Martelletti P
    J Headache Pain; 2015; 17():1. PubMed ID: 26792662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment.
    Guerzoni S; Pellesi L; Baraldi C; Pini LA
    J Headache Pain; 2015; 17():48. PubMed ID: 27146068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.
    Russo M; Manzoni GC; Taga A; Genovese A; Veronesi L; Pasquarella C; Sansebastiano GE; Torelli P
    Neurol Sci; 2016 Jul; 37(7):1127-31. PubMed ID: 27048312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
    J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A; Fontana A; Miscio AM; Zarrelli MM; Copetti M; Leone MA
    Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of onabotulinumtoxinA for chronic migraine.
    Whitcup SM; Turkel CC; DeGryse RE; Brin MF
    Ann N Y Acad Sci; 2014 Nov; 1329():67-80. PubMed ID: 25399521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
    Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Makris N; Kararizou E
    J Headache Pain; 2018 Sep; 19(1):87. PubMed ID: 30225735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine.
    Maasumi K; Thompson NR; Kriegler JS; Tepper SJ
    Headache; 2015 Oct; 55(9):1218-24. PubMed ID: 26381856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.
    Khalil M; Zafar HW; Quarshie V; Ahmed F
    J Headache Pain; 2014 Sep; 15(1):54. PubMed ID: 25178393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic migraine treatment: from OnabotulinumtoxinA onwards.
    Negro A; Curto M; Lionetto L; Giamberardino MA; Martelletti P
    Expert Rev Neurother; 2016 Oct; 16(10):1217-27. PubMed ID: 27310178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.